search
Back to results

Effects of Gallopamil in Severe Asthma (REMODEL'ASTHME)

Primary Purpose

Asthma

Status
Completed
Phase
Phase 2
Locations
France
Study Type
Interventional
Intervention
Methoxyverapamil (gallopamil)
Placebo.
Sponsored by
University Hospital, Bordeaux
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma focused on measuring Asthma, gallopamil, airway remodelling, smooth muscle

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female aged more than 18 years
  • Written informed consent
  • Diagnosis of severe asthma according to ATS criteria

Exclusion Criteria:

  • Smoker or former smoker
  • Chronic viral infections (hepatitis, HIV)
  • Aspergillosis
  • Pregnancy
  • Breastfeeding
  • Contraindications to gallopamil or bronchoscopy

Sites / Locations

  • Hôpital Haut-Lévêque - Centre Hospitalier Universitaire de Bordeaux

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

1

2

Arm Description

16 patients with a diagnosis of severe asthma under gallopamil treatment

16 patients with a diagnosis of severe asthma under placebo treatment

Outcomes

Primary Outcome Measures

Bronchial smooth muscle remodelling assessed by optic microscopy.

Secondary Outcome Measures

Bronchial smooth muscle remodelling assessed by electron microscopy
Bronchial smooth muscle mitochondrial number and activity assessed in vitro
Bronchial thickness assessed by 3D analysis of computed tomography
Asthma control using asthma control questionnaire, inflammation monitoring, number of hospitalizations, number of emergency visits, number of unplanned medical visits.

Full Information

First Posted
May 7, 2009
Last Updated
August 13, 2013
Sponsor
University Hospital, Bordeaux
search

1. Study Identification

Unique Protocol Identification Number
NCT00896428
Brief Title
Effects of Gallopamil in Severe Asthma
Acronym
REMODEL'ASTHME
Official Title
Effects of Gallopamil on Bronchial Smooth Muscle Remodelling in Severe Asthma: a Double Blind Study.
Study Type
Interventional

2. Study Status

Record Verification Date
August 2013
Overall Recruitment Status
Completed
Study Start Date
December 2009 (undefined)
Primary Completion Date
July 2012 (Actual)
Study Completion Date
November 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Bordeaux

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Severe asthma is a difficult to treat disease, characterized by bronchial remodelling, which is an abnormal repair process that contributes to the development of poorly reversible airway narrowing. Such remodelling is now considered as one of the main prognostic factors. Gallopamil-sensitive calcium influx plays a key role in this remodelling process in vitro. The objective of this study is to compare the effects of gallopamil versus placebo on the bronchial smooth muscle remodelling in severe asthmatic patients.
Detailed Description
Bronchial remodelling mainly involves an increased mass of bronchial smooth muscle (BSM), which is related with an increase proliferation of smooth muscle cells. Recently, using BSM cells obtained from severe asthmatics, we have demonstrated that such an increase proliferation was induced by an activation cascade (Trian, J Exp Med, 2007). It first started with a gallopamil-sensitive calcium influx which induced the activation of calcium-calmodulin kinase IV (CamK-IV). CamK-IV then enhanced mitochondrial biogenesis through the subsequent activation of various transcription factors including PGC-1α, NRF-1 and mt-TFA. BSM cell proliferation was mainly mitochondria-dependent in vitro in severe asthma whereas that of controls was virtually mitochondria-independent. However, in vivo effects of gallopamil remain to be investigated. We will thus enrol 32 severe asthmatic patients in a phase 2 randomized double blind study against placebo and evaluate the effect of gallopamil on BSM remodelling. Since inflammation also activates mitochondrial biogenesis in BSM cells, we will initially optimized asthma treatment for 3 months by both controlling co morbidities and decreasing bronchial inflammation using exhaled NO and eosinophil count within the induced sputum. We will then perform fiberoptic fibroscopy before and after 12 month treatment with gallopamil.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
Asthma, gallopamil, airway remodelling, smooth muscle

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
31 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
16 patients with a diagnosis of severe asthma under gallopamil treatment
Arm Title
2
Arm Type
Placebo Comparator
Arm Description
16 patients with a diagnosis of severe asthma under placebo treatment
Intervention Type
Drug
Intervention Name(s)
Methoxyverapamil (gallopamil)
Intervention Description
200 mg/day (1 tablet 100 mg morning and evening) for 12 months.
Intervention Type
Drug
Intervention Name(s)
Placebo.
Intervention Description
1 tablet morning and evening for 12 months
Primary Outcome Measure Information:
Title
Bronchial smooth muscle remodelling assessed by optic microscopy.
Time Frame
Before and after 12 months treatment.
Secondary Outcome Measure Information:
Title
Bronchial smooth muscle remodelling assessed by electron microscopy
Time Frame
Before and after 12 months treatment.
Title
Bronchial smooth muscle mitochondrial number and activity assessed in vitro
Time Frame
Before and after 12 months treatment.
Title
Bronchial thickness assessed by 3D analysis of computed tomography
Time Frame
Before and after 12 months treatment.
Title
Asthma control using asthma control questionnaire, inflammation monitoring, number of hospitalizations, number of emergency visits, number of unplanned medical visits.
Time Frame
Once per month for 12 months.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female aged more than 18 years Written informed consent Diagnosis of severe asthma according to ATS criteria Exclusion Criteria: Smoker or former smoker Chronic viral infections (hepatitis, HIV) Aspergillosis Pregnancy Breastfeeding Contraindications to gallopamil or bronchoscopy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Patrick Berger, Professor
Organizational Affiliation
University Hospital Bordeaux, France
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hôpital Haut-Lévêque - Centre Hospitalier Universitaire de Bordeaux
City
Pessac
ZIP/Postal Code
33604
Country
France

12. IPD Sharing Statement

Citations:
PubMed Identifier
18056286
Citation
Trian T, Benard G, Begueret H, Rossignol R, Girodet PO, Ghosh D, Ousova O, Vernejoux JM, Marthan R, Tunon-de-Lara JM, Berger P. Bronchial smooth muscle remodeling involves calcium-dependent enhanced mitochondrial biogenesis in asthma. J Exp Med. 2007 Dec 24;204(13):3173-81. doi: 10.1084/jem.20070956. Epub 2007 Dec 3.
Results Reference
background
PubMed Identifier
25633090
Citation
Girodet PO, Dournes G, Thumerel M, Begueret H, Dos Santos P, Ozier A, Dupin I, Trian T, Montaudon M, Laurent F, Marthan R, Berger P. Calcium channel blocker reduces airway remodeling in severe asthma. A proof-of-concept study. Am J Respir Crit Care Med. 2015 Apr 15;191(8):876-83. doi: 10.1164/rccm.201410-1874OC.
Results Reference
derived

Learn more about this trial

Effects of Gallopamil in Severe Asthma

We'll reach out to this number within 24 hrs